Summary
In this phase II trial, menogaril was administered to patients with metastatic colon cancer at a dose of 200 mg/m2 IV over one hour with cycles repeated every 28 days provided the absolute granulocyte count was ≥ 2000 cells/μl. Dose adjustments up or down were made depending upon nadir counts. Twenty-four patients were entered on this study with 21 eligible and evaluable for response. There was 1 CR lasting four and one-half months and 1 PR lasting three months for an overall CR \s+ PR rate of 10% with a 95% confidence interval of 1% to 30%. Six patients (29%) had stable disease and 13 (62%) progressed. Median survival is 13.1 months. Toxicity was primarily hematologic with two cases of life-threatening leukopenia (< 1000 cells/μl) and one case of life-threatening granulocytopenia (< 250 cells/μl) among the 21 eligible patients, and one case of life-threatening leukopenia and granulocytopenia in one ineligible patient. There were no deaths due to treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Weiss GR, Bhuyan BK, Kisner DL, Von Hoff DD: 7 (R)-O-Methylnogarol (MEN): antitumor activity in the human tumor cloning system. Invest New Drugs 2: 118, 1984
Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-Methylnogarol and other analogs of the anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63: 1971–1978, 1979
Krueger WC, Pschigoda LM, Schpok SLF, Moscowitz A, McGovren JP, Neta P, Merritt MV, Li LH: The interaction of nogalamycin and analogs with DNA and other biopolymers. Chem-Biol Inter 36: 1–18, 1981
Li LH, Kuentzel SL, Murch LL, Pschigoda LM, Krueger WC: Comparative biological and biochemical effects of nogalamycin and its analogs on L1210 Leukemia. Cancer Res 39: 4816–4822, 1979
Bhuyan BK, Blowers CL, Shugars KD: Lethality of nogalamycin, nogalamycin analogs, and Adriamycin to cells in different cell cycle phases. Cancer Res 40: 3437–3442, 1980
Carter SK, Friedman M: Intregration of chemotherapy into combined modality treatment of solid tumors. II. Large bowel carcinoma. Cancer Treat Rev 1: 111–129, 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Whitehead, R.P., Earhart, R.H., Fleming, T. et al. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. Invest New Drugs 8, 295–297 (1990). https://doi.org/10.1007/BF00171840
Issue Date:
DOI: https://doi.org/10.1007/BF00171840